Dan Constantinescu
Associate, Intellectual Property
Dan Constantinescu is an associate in Willkie’s Intellectual Property Department. With a Ph.D. in the biological sciences, Dan has represented major biopharmaceutical and biotechnology companies in all aspects of patent litigation, including jury trial and appeal, as well as in inter partes review proceedings before the U.S. Patent and Trademark Office. In particular, Dan has extensive experience with BPCIA and Hatch-Waxman patent litigation involving generic and biosimilar drug products. Dan also has experience advising clients regarding due diligence, freedom-to-operate, and patentability studies. His practice has covered various life sciences technologies, including small molecule, protein, and RNA-based therapeutics as well as other technologies, including antibody production, lipid-based drug delivery, gene-editing, and vaccines.
Experience
Dan is a member of the New York Intellectual Property Law Association and the New York State Bar Association.
- Genentech v. Pfizer (bevacizumab) – Currently representing Pfizer in BPCIA litigation concerning Pfizer’s Avastin biosimilar product.
- Pfizer v. Roche – Currently representing Pfizer in IPR proceeding concerning patent related to recombinant antibody technology.
- Genentech v. Hospira (bevacizumab) – Currently representing Hospira in Federal Circuit appeal after obtaining favorable decision in IPR proceeding concerning patent related to Avastin.
- Genentech v. Pfizer (trastuzumab) – Represented Pfizer in BPCIA litigation concerning Pfizer’s Herceptin biosimilar product.
- Amgen v. Hospira (erythropoietin) – Represented Hospira in one of the first BPCIA litigations concerning Hospira’s Epogen biosimilar product.
- Hospira v. Genentech (bevacizumab) – Represented Hospira in successful IPR proceeding concerning patent related to Avastin.
- Hospira v. Euroheath International – Represented Hospira in patent litigation concerning Hospira’s branded Precedex product.
- Takeda v. Actavis (bupropion and naltrexone) – Represented Actavis in patent litigation concerning Actavis’s Contrave generic product.
- Sanofi v. Actavis (cabazitaxel) – Represent Actavis in patent litigation concerning Activis’s Jevtana generic product.
Credentials
Education
University of California College of the Law, San Francisco, J.D., 2012 University of Pittsburgh, PhD, 2008 Haverford College, B.S., 1999
Bar Admissions
Court Admissions
United States District Court, Southern District of New York, 2014